NCT02101684View on ClinicalTrials.gov

Orteronel (TAK-700) in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors. The Greko II Study.

PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

January 11, 2017

Study Completion Date

January 11, 2017

Conditions
Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors
Interventions
DRUG

Orteronel 300mg BID

Trial Locations (9)

14004

Complejo Hospitalario Regional Reina Sofía, Córdoba

15706

Complexo Hospitalario Universitario de Santiago, Santiago de Compostela

28046

Hospital Universitario La Paz, Madrid

28050

Hospital Universitario Madrid Sanchinarro, Madrid

28922

Hospital Universitario Fundación Alcorcón, Alcorcón

31008

Complejo Hospitalario de Navarra, Pamplona

46026

Hospital Universitari I Politècnic La Fe, Valencia

07198

Hospital Son Llatzer, Palma de Mallorca

08003

Hospital Del Mar, Barcelona

Sponsors

Collaborators (1)

Takeda
All Listed Sponsors
collaborator

Takeda

INDUSTRY

lead

Grupo Español de Tumores Huérfanos e Infrecuentes

OTHER

NCT02101684 - Orteronel (TAK-700) in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors. The Greko II Study. | Biotech Hunter | Biotech Hunter